R
Randy D. Gascoyne
Researcher at BC Cancer Agency
Publications - 603
Citations - 47744
Randy D. Gascoyne is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 120, co-authored 603 publications receiving 42898 citations. Previous affiliations of Randy D. Gascoyne include Queen Mary University of London & Vancouver General Hospital.
Papers
More filters
Journal ArticleDOI
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao,Ash A. Alizadeh,Chad Tang,June Helen Myklebust,June Helen Myklebust,Bindu Varghese,Saar Gill,Max Jan,Adriel C. Cha,Charles Chan,Brent T. Tan,Christopher Y. Park,Feifei Zhao,Holbrook E Kohrt,Raquel Malumbres,Javier Briones,Randy D. Gascoyne,Izidore S. Lossos,Ronald Levy,Irving L. Weissman,Ravindra Majeti +20 more
TL;DR: The eradication of human NHL solely with a monoclonal antibody therapy combining rituximab with a blocking anti-CD47 antibody, which synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers.
Journal ArticleDOI
Non-Hodgkin lymphoma.
TL;DR: Since this topic was last reviewed in The Lancet in 2012, advances in understanding the biology and genetics of non-Hodgkin lymphoma and the availability of new diagnostic methods and therapies have improved the ability to manage patients with this disorder.
Journal ArticleDOI
ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project
Kerry J. Savage,Nancy L. Harris,Julie M. Vose,Fred Ullrich,Elaine S. Jaffe,Joseph M. Connors,Lisa M. Rimsza,Stefano Pileri,Mukesh Chhanabhai,Randy D. Gascoyne,James O. Armitage,Dennis D. Weisenburger +11 more
TL;DR: Although the prognosis of ALK(-) ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed.
Journal ArticleDOI
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Béguelin,Relja Popovic,Matt Teater,Yanwen Jiang,Karen L. Bunting,Monica Rosen,Hao Shen,Shao Ning Yang,Ling Wang,Teresa Ezponda,Eva Martinez-Garcia,Haikuo Zhang,Yupeng Zheng,Sharad K. Verma,Michael T. McCabe,Heidi M. Ott,Glenn S. Van Aller,Ryan G. Kruger,Yan Liu,Charles F. McHugh,David Scott,Young Rock Chung,Neil L. Kelleher,Rita Shaknovich,Caretha L. Creasy,Randy D. Gascoyne,Kwok-Kin Wong,Leandro Cerchietti,Ross L. Levine,Omar Abdel-Wahab,Jonathan D. Licht,Olivier Elemento,Ari Melnick +32 more
TL;DR: GC B cell (GCB)-type diffuse large B cell lymphomas (DLBCLs) are mostly addicted to EZH2 but not the more differentiated activated B cell(ABC)-type DLBCLS, thus clarifying the therapeutic scope of EZh2 targeting.
Journal ArticleDOI
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou,Laurie H. Sehn,Alfred Rademaker,Leo I. Gordon,Ann S. LaCasce,Allison Crosby-Thompson,Ann Vanderplas,Andrew D. Zelenetz,Gregory A. Abel,Maria Alma Rodriguez,Auayporn Nademanee,Mark S. Kaminski,Myron S. Czuczman,Michael Millenson,Joyce C. Niland,Randy D. Gascoyne,Joseph M. Connors,Jonathan W. Friedberg,Jane N. Winter +18 more
TL;DR: The NCCN-IPI is easy to apply and more powerful than the IPI for predicting survival in the rituximab era and demonstrated enhanced discrimination for both low- and high-risk patients.